Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.
Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, Landau H, Korde N, Mailankody S, Smith E, Chung DJ, Koehne G, Shah GL, Alexander A, Patel M, Ballagi A, Grundberg I, Giralt SA, Landgren O. Lendvai N, et al. Leuk Lymphoma. 2018 Aug;59(8):1981-1985. doi: 10.1080/10428194.2017.1403020. Epub 2018 Jan 8. Leuk Lymphoma. 2018. PMID: 29308691 Free PMC article. No abstract available.
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
Zamarin D, Devlin SM, Arcila ME, Landau H, Lesokhin A, Lendvai N, Chung DJ, Chimento D, Weltz J, Babu D, Giralt S, Hassoun H. Zamarin D, et al. Among authors: lendvai n. Leukemia. 2013 Dec;27(12):2422-4. doi: 10.1038/leu.2013.126. Epub 2013 Apr 23. Leukemia. 2013. PMID: 23608883 No abstract available.
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.
Ogunniyi A, Rodriguez M, Devlin S, Adel N, Landau H, Chung DJ, Lendvai N, Lesokhin A, Koehne G, Mailankody S, Korde N, Reich L, Landgren O, Giralt S, Hassoun H. Ogunniyi A, et al. Among authors: lendvai n. Leuk Lymphoma. 2017 May;58(5):1123-1129. doi: 10.1080/10428194.2016.1239261. Epub 2016 Oct 13. Leuk Lymphoma. 2017. PMID: 27735212 Free PMC article.
Proteomic profiling in plasma cell disorders: a feasibility study.
Mailankody S, Devlin SM, Korde N, Lendvai N, Lesokhin A, Landau H, Hassoun H, Ballagi A, Ekman D, Chung DJ, Patel M, Koehne G, Giralt S, Landgren O. Mailankody S, et al. Among authors: lendvai n. Leuk Lymphoma. 2017 Jul;58(7):1757-1759. doi: 10.1080/10428194.2016.1258699. Epub 2016 Dec 2. Leuk Lymphoma. 2017. PMID: 27908223 Free PMC article. No abstract available.
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
Shah GL, Landau H, Londono D, Devlin SM, Kosuri S, Lesokhin AM, Lendvai N, Hassoun H, Chung DJ, Koehne G, Jhanwar SC, Landgren O, Levine R, Giralt SA. Shah GL, et al. Among authors: lendvai n. Leuk Lymphoma. 2017 Aug;58(8):1823-1831. doi: 10.1080/10428194.2016.1260126. Epub 2017 Jan 12. Leuk Lymphoma. 2017. PMID: 28078910 Free PMC article.
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.
Hassoun H, Roshal M, Sabari J, Nguyen J, Gao Q, Devlin SM, Landau H, Lendvai N, Chung DJ, Lesokhin AM, Korde N, Mailankody S, Dogan A, Giralt SA, Landgren CO. Hassoun H, et al. Among authors: lendvai n. Leuk Lymphoma. 2017 Dec;58(12):2962-2965. doi: 10.1080/10428194.2017.1312382. Epub 2017 May 9. Leuk Lymphoma. 2017. PMID: 28482750 No abstract available.
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Salcedo M, Lendvai N, Mastey D, Schlossman J, Hultcrantz M, Korde N, Mailankody S, Lesokhin A, Hassoun H, Smith E, Shah U, Diab V, Werner K, Landau H, Lahoud O, Drullinsky P, Shah G, Chung D, Scordo M, Giralt S, Landgren O. Salcedo M, et al. Among authors: lendvai n. Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):198-200. doi: 10.1016/j.clml.2019.12.013. Epub 2019 Dec 26. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32001193 Free PMC article. Clinical Trial. No abstract available.
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
Lahoud OB, Landau H, Nguyen J, Devlin S, Lendvai N, Weltz J, Ayorinde T, Chung DJ, Lesokhin AM, Kewalramani T, Korde N, Mailankody S, Landgren O, Giralt S, Comenzo RL, Hassoun H. Lahoud OB, et al. Among authors: lendvai n. Leuk Lymphoma. 2022 Sep;63(9):2126-2135. doi: 10.1080/10428194.2022.2062347. Epub 2022 Jun 1. Leuk Lymphoma. 2022. PMID: 35648041 Free PMC article. Clinical Trial.
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center.
Pozotrigo M, Adel N, Landau H, Lesokhin A, Lendvai N, Chung DJ, Chimento D, Riedel E, Chen X, Reich L, Comenzo R, Giralt S, Hassoun H. Pozotrigo M, et al. Among authors: lendvai n. Bone Marrow Transplant. 2013 Aug;48(8):1033-9. doi: 10.1038/bmt.2012.281. Epub 2013 Jan 21. Bone Marrow Transplant. 2013. PMID: 23334269
58 results